Global Female Sexual Dysfunction Treatment Market 2023-2027

Description

List of Tables

Technavio has been monitoring the female sexual dysfunction treatment market and it is poised to grow by $7760.77 mn during 2023-2027, accelerating at a CAGR of 34.28% during the forecast period. Our report on the female sexual dysfunction treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases, growing awareness of female sexual dysfunction, and approval and availability of drugs to treat hypoactive sexual desire disorder.

Technavio's female sexual dysfunction treatment market is segmented as below:

By Age Group

Above 40 years
Below 40 years

By Product

Non-hormonal therapy
Hormonal therapy

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increasing R&D for the treatment of sexual dysfunction in women as one of the prime reasons driving the female sexual dysfunction treatment market growth during the next few years. Also, safety label changes for female sexual dysfunction therapy and increasing use of drugs causing sexual dysfunction in women will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the female sexual dysfunction treatment market covers the following areas:

Female sexual dysfunction treatment market sizing
Female sexual dysfunction treatment market forecast
Female sexual dysfunction treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female sexual dysfunction treatment market vendors that include Assos Ilac, Cipla Ltd., Dare Bioscience Inc., Dr Reddys Laboratories Ltd., Duchesnay Inc., Endo International Plc, Freya Pharma Solutions B.V., Lupin Ltd., Mithra Pharmaceuticals SA, Novo Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Pharmbio Korea Inc., Sprout Pharmaceuticals Inc., Strategic Science and Technologies LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the female sexual dysfunction treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR70409

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Age Group
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global female sexual dysfunction treatment market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global female sexual dysfunction treatment market 2017 - 2021 ($ million)
4.2 Age Group Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Age Group Segment 2017 - 2021 ($ million)
4.3 Product Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Age Group

6.1 Market segments
Exhibit 30: Chart on Age Group - Market share 2022-2027 (%)
Exhibit 31: Data Table on Age Group - Market share 2022-2027 (%)
6.2 Comparison by Age Group
Exhibit 32: Chart on Comparison by Age Group
Exhibit 33: Data Table on Comparison by Age Group
6.3 Above 40 years - Market size and forecast 2022-2027
Exhibit 34: Chart on Above 40 years - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Above 40 years - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Above 40 years - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Above 40 years - Year-over-year growth 2022-2027 (%)
6.4 Below 40 years - Market size and forecast 2022-2027
Exhibit 38: Chart on Below 40 years - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Below 40 years - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Below 40 years - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Below 40 years - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Age Group
Exhibit 42: Market opportunity by Age Group ($ million)

7 Market Segmentation by Product

7.1 Market segments
Exhibit 43: Chart on Product - Market share 2022-2027 (%)
Exhibit 44: Data Table on Product - Market share 2022-2027 (%)
7.2 Comparison by Product
Exhibit 45: Chart on Comparison by Product
Exhibit 46: Data Table on Comparison by Product
7.3 Non-hormonal therapy - Market size and forecast 2022-2027
Exhibit 47: Chart on Non-hormonal therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Data Table on Non-hormonal therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 49: Chart on Non-hormonal therapy - Year-over-year growth 2022-2027 (%)
Exhibit 50: Data Table on Non-hormonal therapy - Year-over-year growth 2022-2027 (%)
7.4 Hormonal therapy - Market size and forecast 2022-2027
Exhibit 51: Chart on Hormonal therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 52: Data Table on Hormonal therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Chart on Hormonal therapy - Year-over-year growth 2022-2027 (%)
Exhibit 54: Data Table on Hormonal therapy - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Product
Exhibit 55: Market opportunity by Product ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 57: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 58: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 59: Chart on Geographic comparison
Exhibit 60: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Canada - Market size and forecast 2022-2027
Exhibit 81: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 82: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 83: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.9 Germany - Market size and forecast 2022-2027
Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.10 UK - Market size and forecast 2022-2027
Exhibit 89: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 90: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 91: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.11 France - Market size and forecast 2022-2027
Exhibit 93: Chart on France - Market size and forecast 2022-2027 ($ million)
Exhibit 94: Data Table on France - Market size and forecast 2022-2027 ($ million)
Exhibit 95: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on France - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 97: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 98: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 99: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 100: Overview on factors of disruption
11.4 Industry risks
Exhibit 101: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 102: Vendors covered
12.2 Market positioning of vendors
Exhibit 103: Matrix on vendor position and classification
12.3 Cipla Ltd.
Exhibit 104: Cipla Ltd. - Overview
Exhibit 105: Cipla Ltd. - Business segments
Exhibit 106: Cipla Ltd. - Key news
Exhibit 107: Cipla Ltd. - Key offerings
Exhibit 108: Cipla Ltd. - Segment focus
12.4 Dare Bioscience Inc.
Exhibit 109: Dare Bioscience Inc. - Overview
Exhibit 110: Dare Bioscience Inc. - Product / Service
Exhibit 111: Dare Bioscience Inc. - Key offerings
12.5 Dr Reddys Laboratories Ltd.
Exhibit 112: Dr Reddys Laboratories Ltd. - Overview
Exhibit 113: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 114: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 115: Dr Reddys Laboratories Ltd. - Segment focus
12.6 Duchesnay Inc.
Exhibit 116: Duchesnay Inc. - Overview
Exhibit 117: Duchesnay Inc. - Product / Service
Exhibit 118: Duchesnay Inc. - Key offerings
12.7 Endo International Plc
Exhibit 119: Endo International Plc - Overview
Exhibit 120: Endo International Plc - Business segments
Exhibit 121: Endo International Plc - Key news
Exhibit 122: Endo International Plc - Key offerings
Exhibit 123: Endo International Plc - Segment focus
12.8 Freya Pharma Solutions B.V.
Exhibit 124: Freya Pharma Solutions B.V. - Overview
Exhibit 125: Freya Pharma Solutions B.V. - Product / Service
Exhibit 126: Freya Pharma Solutions B.V. - Key offerings
12.9 Lupin Ltd.
Exhibit 127: Lupin Ltd. - Overview
Exhibit 128: Lupin Ltd. - Product / Service
Exhibit 129: Lupin Ltd. - Key news
Exhibit 130: Lupin Ltd. - Key offerings
12.10 Mithra Pharmaceuticals SA
Exhibit 131: Mithra Pharmaceuticals SA - Overview
Exhibit 132: Mithra Pharmaceuticals SA - Product / Service
Exhibit 133: Mithra Pharmaceuticals SA - Key offerings
12.11 Novo Nordisk AS
Exhibit 134: Novo Nordisk AS - Overview
Exhibit 135: Novo Nordisk AS - Business segments
Exhibit 136: Novo Nordisk AS - Key offerings
Exhibit 137: Novo Nordisk AS - Segment focus
12.12 Palatin Technologies Inc.
Exhibit 138: Palatin Technologies Inc. - Overview
Exhibit 139: Palatin Technologies Inc. - Product / Service
Exhibit 140: Palatin Technologies Inc. - Key offerings
12.13 Pfizer Inc.
Exhibit 141: Pfizer Inc. - Overview
Exhibit 142: Pfizer Inc. - Product / Service
Exhibit 143: Pfizer Inc. - Key news
Exhibit 144: Pfizer Inc. - Key offerings
12.14 Sprout Pharmaceuticals Inc.
Exhibit 145: Sprout Pharmaceuticals Inc. - Overview
Exhibit 146: Sprout Pharmaceuticals Inc. - Product / Service
Exhibit 147: Sprout Pharmaceuticals Inc. - Key offerings
12.15 Strategic Science and Technologies LLC
Exhibit 148: Strategic Science and Technologies LLC - Overview
Exhibit 149: Strategic Science and Technologies LLC - Product / Service
Exhibit 150: Strategic Science and Technologies LLC - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 151: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 152: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 153: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 154: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 155: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Viatris Inc.
Exhibit 156: Viatris Inc. - Overview
Exhibit 157: Viatris Inc. - Business segments
Exhibit 158: Viatris Inc. - Key offerings
Exhibit 159: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 160: Inclusions checklist
Exhibit 161: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 162: Currency conversion rates for US$
13.4 Research methodology
Exhibit 163: Research methodology
Exhibit 164: Validation techniques employed for market sizing
Exhibit 165: Information sources
13.5 List of abbreviations
Exhibit 166: List of abbreviations